Selank: the Soviet anxiolytic that doesn't sedate.

The strangest thing about Selank is the silence around it in the West. A heptapeptide approved for generalized anxiety disorder in a country with a serious psychiatric research tradition, with two decades of clinical data behind it, and yet Western pharmacology textbooks rarely mention the molecule by name. The reasons are partly geopolitical, partly linguistic, and partly methodological: the bulk of the Selank literature is in Russian, the trials are small by FDA standards, and the compound has never been pursued by a Western sponsor.

But the file is real. And it describes something unusual: an anxiolytic that, in head-to-head comparisons against medazepam, produces a similar reduction in symptom severity without the cognitive blunting, the rebound, or the dependence that defines the benzodiazepine class.

A peptide born from an immune signal

Selank's origin sits in a 1970s observation about a four-amino-acid fragment of immunoglobulin G's Fc region. The fragment, named tuftsin (Thr-Lys-Pro-Arg) after Tufts University where it was first characterized, behaved like a small immunological signaling molecule — phagocyte-activating, antimicrobial, with effects that extended into the central nervous system in ways no one quite expected from an immune oligopeptide.

At the Institute of Molecular Genetics of the Russian Academy of Sciences, a group led by Nikolai Myasoedov took tuftsin as a starting point and asked a different question: could you stabilize the molecule against rapid plasmatic degradation, preserve the central effects, and tune the immunological activity into something more like a selective neuropsychiatric agent? The answer, after iterating through analogs across the 1980s, was Selank — tuftsin extended at the C-terminus by a Pro-Gly-Pro sequence that resists peptidase cleavage.

Mechanism, in plain language

Selank is what pharmacologists call a multi-target small peptide. Rather than locking onto a single receptor, it perturbs several interconnected systems at once, each at a modest amplitude. The composite effect is anxiolytic without the steep sedation curve.

• GABAergic signaling: Selank shifts the expression of GABA-A receptor subunit genes in cultured human neuroblastoma cells, suggesting it primes the same inhibitory system benzodiazepines act on, but indirectly and at the transcriptional level.
• Serotonergic and dopaminergic balance: animal studies show Selank corrects stress-induced shifts in 5-HT and dopamine turnover.
• BDNF upregulation: chronic Selank elevates brain-derived neurotrophic factor mRNA in regions associated with memory and executive function.
• Enkephalin metabolism: Selank inhibits the enzymes that break down endogenous opioid peptides, prolonging the action of the body's own anti-stress signals.

What unites these effects is restoration rather than suppression. Benzodiazepines flatten arousal by amplifying inhibitory tone across the cortex; Selank appears to nudge several stress-response systems back toward their unstressed baselines. The clinical translation is a compound that lowers anxiety while leaving working memory and reaction time intact.

Beyond the obvious

The non-anxiolytic findings are where Selank gets genuinely interesting. Microarray studies have tracked transcriptional changes in animal hippocampus and human cell lines after Selank exposure and found that the peptide moves several hundred genes, not just the GABA-A subunits. A meaningful fraction of those transcripts are immune-related — consistent with Selank's lineage from tuftsin.

Russian work has reported modulation of cytokine balance, particularly in the IL-6 and interferon families, in stressed animals receiving Selank. There are also scattered reports of metabolic effects — shifts in lipid handling and glucose response in chronically stressed rodents — that have not yet been pursued in humans but suggest the compound's reach extends beyond the brain.

Selank's anxiolytic magnitude is in the medazepam range — without the cognitive cost, the rebound, or the dependence.

Adjacent research

In the Russian neuropsychopharmacology literature, Selank is rarely discussed alone. It is paired, almost reflexively, with Semax — another heptapeptide from the same Moscow institute, derived from a fragment of ACTH and tuned for cognitive rather than anxiolytic effect. The two are often studied alongside one another because they share an institutional lineage and a structural philosophy: short, peptidase-stabilized sequences modeled on endogenous regulators, designed for intranasal administration.

Practical considerations

Selank is supplied as a lyophilized powder for reconstitution, with intranasal administration the route used in nearly all clinical and animal work. The peptide does not survive oral digestion. In the United States it is sold strictly for research use; it has no FDA-approved indication.